[123I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration
Identifieur interne : 002B13 ( PascalFrancis/Corpus ); précédent : 002B12; suivant : 002B14[123I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration
Auteurs : Walter Pirker ; Susanne Asenbaum ; Gerhard Bencsits ; Daniela Prayer ; Willibald Gerschlager ; Lüder Deecke ; Thomas BrückeSource :
- Movement disorders [ 0885-3185 ] ; 2000.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Differentiation between Parkinson's disease (PD) and other neurodegenerative disorders with parkinsonian features, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), is difficult on clinical grounds. We studied the pattern of dopaminergic degeneration in 18 patients with probable MSA, 8 patients with PSP, 4 patients with CBD, 48 patients with PD and a similar degree of disability, and 14 control subjects performing single photon emission computed tomography (SPECT) 20 hours after injection of [123I]β-CIT. Overall striatal binding was significantly reduced in MSA (-51% of normal mean), PSP (-60%), CBD (-35%), and PD (-58%), without overlap with control values. Asymmetry of striatal β-CIT binding was significantly increased in patients with CBD and PD, as compared with control subjects. Although asymmetry seemed to be less pronounced in MSA and PSP than in PD, this was not statistically significant. Putamen-caudate nucleus ratios in patients with PD, MSA, and PSP, but not with CBD, were significantly reduced, as compared with control subjects. In conclusion, [123I]β-CIT SPECT reliably enables the visualization of the presynaptic dopaminergic lesion in patients with MSA, PSP, and CBD. In most patients, however, it does not seem to be possible to differentiate these disorders from PD with this method.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 01-0016454 INIST |
|---|---|
| ET : | [123I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration |
| AU : | PIRKER (Walter); ASENBAUM (Susanne); BENCSITS (Gerhard); PRAYER (Daniela); GERSCHLAGER (Willibald); DEECKE (Lüder); BRÜCKE (Thomas) |
| AF : | Department of Clinical Neurology, University of Vienna/Vienna/Autriche (1 aut., 2 aut., 5 aut., 6 aut.); Department of Nuclear Medicine, University of Vienna/Vienna/Autriche (2 aut.); Department of Neurology, Wilhelminenspital der Stadt Wien/Vienna/Autriche (3 aut., 7 aut.); Department of Radiology, University of Vienna/Vienna/Autriche (4 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2000; Vol. 15; No. 6; Pp. 1158-1167; Bibl. 38 ref. |
| LA : | Anglais |
| EA : | Differentiation between Parkinson's disease (PD) and other neurodegenerative disorders with parkinsonian features, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), is difficult on clinical grounds. We studied the pattern of dopaminergic degeneration in 18 patients with probable MSA, 8 patients with PSP, 4 patients with CBD, 48 patients with PD and a similar degree of disability, and 14 control subjects performing single photon emission computed tomography (SPECT) 20 hours after injection of [123I]β-CIT. Overall striatal binding was significantly reduced in MSA (-51% of normal mean), PSP (-60%), CBD (-35%), and PD (-58%), without overlap with control values. Asymmetry of striatal β-CIT binding was significantly increased in patients with CBD and PD, as compared with control subjects. Although asymmetry seemed to be less pronounced in MSA and PSP than in PD, this was not statistically significant. Putamen-caudate nucleus ratios in patients with PD, MSA, and PSP, but not with CBD, were significantly reduced, as compared with control subjects. In conclusion, [123I]β-CIT SPECT reliably enables the visualization of the presynaptic dopaminergic lesion in patients with MSA, PSP, and CBD. In most patients, however, it does not seem to be possible to differentiate these disorders from PD with this method. |
| CC : | 002B17G |
| FD : | Ophtalmoplégie supranucléaire; Atrophie multisystématisée; Parkinson maladie; Dégénérescence; Cortex cérébral; Noyau gris central; Tomoscintigraphie; Photon; Neurone dopaminergique; Diagnostic différentiel; Etude comparative; Adulte |
| FG : | Homme; Oeil pathologie; Oculomotricité syndrome; Système nerveux pathologie; Système nerveux central pathologie; Tronc cérébral syndrome; Encéphale pathologie; Maladie dégénérative; Exploration radioisotopique |
| ED : | Supranuclear ophthalmoplegia; Multiple system atrophy; Parkinson disease; Degeneration; Cerebral cortex; Basal ganglion; Emission tomography; Photon; Dopaminergic neuron; Differential diagnostic; Comparative study; Adult |
| EG : | Human; Eye disease; Oculomotor syndrome; Nervous system diseases; Central nervous system disease; Brain stem syndrome; Cerebral disorder; Degenerative disease; Radionuclide study |
| SD : | Oftalmoplejía supranuclear; Atrofia multisistematizada; Parkinson enfermedad; Degeneración; Corteza cerebral; Núcleo basal; Tomocentelleografía; Fotón; Neurona dopaminérgica; Diagnóstico diferencial; Estudio comparativo; Adulto |
| LO : | INIST-20953.354000092814950150 |
| ID : | 01-0016454 |
Links to Exploration step
Pascal:01-0016454Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">[<sup>123</sup>I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration</title><author><name sortKey="Pirker, Walter" sort="Pirker, Walter" uniqKey="Pirker W" first="Walter" last="Pirker">Walter Pirker</name><affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurology, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name><affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurology, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Department of Nuclear Medicine, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bencsits, Gerhard" sort="Bencsits, Gerhard" uniqKey="Bencsits G" first="Gerhard" last="Bencsits">Gerhard Bencsits</name><affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Wilhelminenspital der Stadt Wien</s1><s2>Vienna</s2><s3>AUT</s3><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Prayer, Daniela" sort="Prayer, Daniela" uniqKey="Prayer D" first="Daniela" last="Prayer">Daniela Prayer</name><affiliation><inist:fA14 i1="04"><s1>Department of Radiology, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name><affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurology, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Deecke, Luder" sort="Deecke, Luder" uniqKey="Deecke L" first="Lüder" last="Deecke">Lüder Deecke</name><affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurology, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Brucke, Thomas" sort="Brucke, Thomas" uniqKey="Brucke T" first="Thomas" last="Brücke">Thomas Brücke</name><affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Wilhelminenspital der Stadt Wien</s1><s2>Vienna</s2><s3>AUT</s3><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">01-0016454</idno><date when="2000">2000</date><idno type="stanalyst">PASCAL 01-0016454 INIST</idno><idno type="RBID">Pascal:01-0016454</idno><idno type="wicri:Area/PascalFrancis/Corpus">002B13</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">[<sup>123</sup>I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration</title><author><name sortKey="Pirker, Walter" sort="Pirker, Walter" uniqKey="Pirker W" first="Walter" last="Pirker">Walter Pirker</name><affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurology, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name><affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurology, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Department of Nuclear Medicine, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Bencsits, Gerhard" sort="Bencsits, Gerhard" uniqKey="Bencsits G" first="Gerhard" last="Bencsits">Gerhard Bencsits</name><affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Wilhelminenspital der Stadt Wien</s1><s2>Vienna</s2><s3>AUT</s3><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Prayer, Daniela" sort="Prayer, Daniela" uniqKey="Prayer D" first="Daniela" last="Prayer">Daniela Prayer</name><affiliation><inist:fA14 i1="04"><s1>Department of Radiology, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name><affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurology, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Deecke, Luder" sort="Deecke, Luder" uniqKey="Deecke L" first="Lüder" last="Deecke">Lüder Deecke</name><affiliation><inist:fA14 i1="01"><s1>Department of Clinical Neurology, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Brucke, Thomas" sort="Brucke, Thomas" uniqKey="Brucke T" first="Thomas" last="Brücke">Thomas Brücke</name><affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Wilhelminenspital der Stadt Wien</s1><s2>Vienna</s2><s3>AUT</s3><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2000">2000</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Basal ganglion</term><term>Cerebral cortex</term><term>Comparative study</term><term>Degeneration</term><term>Differential diagnostic</term><term>Dopaminergic neuron</term><term>Emission tomography</term><term>Multiple system atrophy</term><term>Parkinson disease</term><term>Photon</term><term>Supranuclear ophthalmoplegia</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Ophtalmoplégie supranucléaire</term><term>Atrophie multisystématisée</term><term>Parkinson maladie</term><term>Dégénérescence</term><term>Cortex cérébral</term><term>Noyau gris central</term><term>Tomoscintigraphie</term><term>Photon</term><term>Neurone dopaminergique</term><term>Diagnostic différentiel</term><term>Etude comparative</term><term>Adulte</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Differentiation between Parkinson's disease (PD) and other neurodegenerative disorders with parkinsonian features, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), is difficult on clinical grounds. We studied the pattern of dopaminergic degeneration in 18 patients with probable MSA, 8 patients with PSP, 4 patients with CBD, 48 patients with PD and a similar degree of disability, and 14 control subjects performing single photon emission computed tomography (SPECT) 20 hours after injection of [<sup>123</sup>I]β-CIT. Overall striatal binding was significantly reduced in MSA (-51% of normal mean), PSP (-60%), CBD (-35%), and PD (-58%), without overlap with control values. Asymmetry of striatal β-CIT binding was significantly increased in patients with CBD and PD, as compared with control subjects. Although asymmetry seemed to be less pronounced in MSA and PSP than in PD, this was not statistically significant. Putamen-caudate nucleus ratios in patients with PD, MSA, and PSP, but not with CBD, were significantly reduced, as compared with control subjects. In conclusion, [<sup>123</sup>I]β-CIT SPECT reliably enables the visualization of the presynaptic dopaminergic lesion in patients with MSA, PSP, and CBD. In most patients, however, it does not seem to be possible to differentiate these disorders from PD with this method.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>15</s2></fA05><fA06><s2>6</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>[<sup>123</sup>I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration</s1></fA08><fA11 i1="01" i2="1"><s1>PIRKER (Walter)</s1></fA11><fA11 i1="02" i2="1"><s1>ASENBAUM (Susanne)</s1></fA11><fA11 i1="03" i2="1"><s1>BENCSITS (Gerhard)</s1></fA11><fA11 i1="04" i2="1"><s1>PRAYER (Daniela)</s1></fA11><fA11 i1="05" i2="1"><s1>GERSCHLAGER (Willibald)</s1></fA11><fA11 i1="06" i2="1"><s1>DEECKE (Lüder)</s1></fA11><fA11 i1="07" i2="1"><s1>BRÜCKE (Thomas)</s1></fA11><fA14 i1="01"><s1>Department of Clinical Neurology, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Nuclear Medicine, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Neurology, Wilhelminenspital der Stadt Wien</s1><s2>Vienna</s2><s3>AUT</s3><sZ>3 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Radiology, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>4 aut.</sZ></fA14><fA20><s1>1158-1167</s1></fA20><fA21><s1>2000</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000092814950150</s5></fA43><fA44><s0>0000</s0><s1>© 2001 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>38 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>01-0016454</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Differentiation between Parkinson's disease (PD) and other neurodegenerative disorders with parkinsonian features, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), is difficult on clinical grounds. We studied the pattern of dopaminergic degeneration in 18 patients with probable MSA, 8 patients with PSP, 4 patients with CBD, 48 patients with PD and a similar degree of disability, and 14 control subjects performing single photon emission computed tomography (SPECT) 20 hours after injection of [<sup>123</sup>I]β-CIT. Overall striatal binding was significantly reduced in MSA (-51% of normal mean), PSP (-60%), CBD (-35%), and PD (-58%), without overlap with control values. Asymmetry of striatal β-CIT binding was significantly increased in patients with CBD and PD, as compared with control subjects. Although asymmetry seemed to be less pronounced in MSA and PSP than in PD, this was not statistically significant. Putamen-caudate nucleus ratios in patients with PD, MSA, and PSP, but not with CBD, were significantly reduced, as compared with control subjects. In conclusion, [<sup>123</sup>I]β-CIT SPECT reliably enables the visualization of the presynaptic dopaminergic lesion in patients with MSA, PSP, and CBD. In most patients, however, it does not seem to be possible to differentiate these disorders from PD with this method.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Ophtalmoplégie supranucléaire</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Supranuclear ophthalmoplegia</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Oftalmoplejía supranuclear</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Atrophie multisystématisée</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Multiple system atrophy</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Atrofia multisistematizada</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Dégénérescence</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Degeneration</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Degeneración</s0><s5>07</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Cortex cérébral</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Cerebral cortex</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Corteza cerebral</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Noyau gris central</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Basal ganglion</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Núcleo basal</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Tomoscintigraphie</s0><s5>10</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Emission tomography</s0><s5>10</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Tomocentelleografía</s0><s5>10</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Photon</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Photon</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Fotón</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Neurone dopaminergique</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Dopaminergic neuron</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Neurona dopaminérgica</s0><s5>13</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Diagnostic différentiel</s0><s5>17</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Differential diagnostic</s0><s5>17</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Diagnóstico diferencial</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Etude comparative</s0><s5>18</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Comparative study</s0><s5>18</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Estudio comparativo</s0><s5>18</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Adulte</s0><s5>20</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Adult</s0><s5>20</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Adulto</s0><s5>20</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Human</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Oeil pathologie</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Eye disease</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Ojo patología</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Oculomotricité syndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Oculomotor syndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Oculomotricidad síndrome</s0><s5>38</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>39</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Tronc cérébral syndrome</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Brain stem syndrome</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Tallo encefalico sindrome</s0><s5>41</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>42</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>42</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>42</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>43</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>43</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>43</s5></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Exploration radioisotopique</s0><s5>61</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Radionuclide study</s0><s5>61</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Exploración radioisotópica</s0><s5>61</s5></fC07><fN21><s1>008</s1></fN21></pA></standard><server><NO>PASCAL 01-0016454 INIST</NO><ET>[<sup>123</sup>I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration</ET><AU>PIRKER (Walter); ASENBAUM (Susanne); BENCSITS (Gerhard); PRAYER (Daniela); GERSCHLAGER (Willibald); DEECKE (Lüder); BRÜCKE (Thomas)</AU><AF>Department of Clinical Neurology, University of Vienna/Vienna/Autriche (1 aut., 2 aut., 5 aut., 6 aut.); Department of Nuclear Medicine, University of Vienna/Vienna/Autriche (2 aut.); Department of Neurology, Wilhelminenspital der Stadt Wien/Vienna/Autriche (3 aut., 7 aut.); Department of Radiology, University of Vienna/Vienna/Autriche (4 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2000; Vol. 15; No. 6; Pp. 1158-1167; Bibl. 38 ref.</SO><LA>Anglais</LA><EA>Differentiation between Parkinson's disease (PD) and other neurodegenerative disorders with parkinsonian features, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), is difficult on clinical grounds. We studied the pattern of dopaminergic degeneration in 18 patients with probable MSA, 8 patients with PSP, 4 patients with CBD, 48 patients with PD and a similar degree of disability, and 14 control subjects performing single photon emission computed tomography (SPECT) 20 hours after injection of [<sup>123</sup>I]β-CIT. Overall striatal binding was significantly reduced in MSA (-51% of normal mean), PSP (-60%), CBD (-35%), and PD (-58%), without overlap with control values. Asymmetry of striatal β-CIT binding was significantly increased in patients with CBD and PD, as compared with control subjects. Although asymmetry seemed to be less pronounced in MSA and PSP than in PD, this was not statistically significant. Putamen-caudate nucleus ratios in patients with PD, MSA, and PSP, but not with CBD, were significantly reduced, as compared with control subjects. In conclusion, [<sup>123</sup>I]β-CIT SPECT reliably enables the visualization of the presynaptic dopaminergic lesion in patients with MSA, PSP, and CBD. In most patients, however, it does not seem to be possible to differentiate these disorders from PD with this method.</EA><CC>002B17G</CC><FD>Ophtalmoplégie supranucléaire; Atrophie multisystématisée; Parkinson maladie; Dégénérescence; Cortex cérébral; Noyau gris central; Tomoscintigraphie; Photon; Neurone dopaminergique; Diagnostic différentiel; Etude comparative; Adulte</FD><FG>Homme; Oeil pathologie; Oculomotricité syndrome; Système nerveux pathologie; Système nerveux central pathologie; Tronc cérébral syndrome; Encéphale pathologie; Maladie dégénérative; Exploration radioisotopique</FG><ED>Supranuclear ophthalmoplegia; Multiple system atrophy; Parkinson disease; Degeneration; Cerebral cortex; Basal ganglion; Emission tomography; Photon; Dopaminergic neuron; Differential diagnostic; Comparative study; Adult</ED><EG>Human; Eye disease; Oculomotor syndrome; Nervous system diseases; Central nervous system disease; Brain stem syndrome; Cerebral disorder; Degenerative disease; Radionuclide study</EG><SD>Oftalmoplejía supranuclear; Atrofia multisistematizada; Parkinson enfermedad; Degeneración; Corteza cerebral; Núcleo basal; Tomocentelleografía; Fotón; Neurona dopaminérgica; Diagnóstico diferencial; Estudio comparativo; Adulto</SD><LO>INIST-20953.354000092814950150</LO><ID>01-0016454</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002B13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:01-0016454
|texte= [123I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration
}}
| This area was generated with Dilib version V0.6.23. |  |